Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 273

Showing 26-50 of 273 citing articles:

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 50
Regulation of body weight: Lessons learned from bariatric surgery
Vance L. Albaugh, Yanlin He, Heike Münzberg, et al.
Molecular Metabolism (2022) Vol. 68, pp. 101517-101517
Open Access | Times Cited: 48
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Maurício Reis Pedrosa, Denise Reis Franco, Hannah Waisberg Gieremek, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 11, pp. 867-884
Closed Access | Times Cited: 47
Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
Jesse Richards, Neha Bang, Erin L. Ratliff, et al.
Obesity Pillars (2023) Vol. 7, pp. 100080-100080
Open Access | Times Cited: 36
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33
Current and future pharmacotherapies for obesity in children and adolescents
Aaron S. Kelly
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 534-541
Closed Access | Times Cited: 28
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake
Sevag Hamamah, Arman Amin, Abdul Latif Al-Kassir, et al.
Nutrients (2023) Vol. 15, Iss. 15, pp. 3365-3365
Open Access | Times Cited: 26
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, et al.
Healthcare (2023) Vol. 11, Iss. 3, pp. 433-433
Open Access | Times Cited: 24
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Rong Cao, Huimin Tian, Yu Zhang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
Wenting Cai, Ruobin Zhang, Yao Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 14
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
Hannah Moll, E.A. Frey, Philipp A. Gerber, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102661-102661
Open Access | Times Cited: 14
Integrating network pharmacology and animal experimental validation to investigate the action mechanism of oleanolic acid in obesity
Tianfeng Liu, Jiliang Wang, Ying Tong, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
Laurence Aoun, Shaza Almardini, Fares Saliba, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 35, pp. 100333-100333
Open Access | Times Cited: 12
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity
Stephanie W. Waldrop, Veronica R. Johnson, Fatima Cody Stanford
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 22-25
Closed Access | Times Cited: 11
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1297-1314
Open Access | Times Cited: 11
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease
Weronika Frąk, Bartłomiej Dąbek, Marta Balcerczyk-Lis, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 687-687
Open Access | Times Cited: 11
Current and future state of pharmacological management of pediatric obesity
Claudia K. Fox, Aaron S. Kelly, Jessica L. Reilly, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 10
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function
Wenran Ren, Jianhui Chen, Wenjing Wang, et al.
Neuron (2024) Vol. 112, Iss. 6, pp. 972-990.e8
Open Access | Times Cited: 9
Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Bingwen Ding, Zhu Zhu, Cong Guo, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 2006-2025
Open Access | Times Cited: 9
Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound
Conner M Willson, L. Patel, Peter G. Middleton, et al.
Cureus (2024)
Open Access | Times Cited: 9
Adiposity, type 2 diabetes and atherosclerotic cardiovascular disease risk: Use and abuse of the body mass index
Benoît J. Arsenault, André C. Carpentier, Paul Poirier, et al.
Atherosclerosis (2024) Vol. 394, pp. 117546-117546
Open Access | Times Cited: 9
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9

Scroll to top